This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Pere Domingo, MD; Silvia Ferrer, MD; Lillian Kolle, MD; Carmen Muñoz, MD; Purificacin Rodriguez, MD
Barcelona, Spain

Arch Intern Med. 1996;156(9):1029-1032.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The pentavalent antimony sodium stibogluconate is the drug of choice in the treatment of visceral leishmaniasis. However, sodium stibogluconate can cause severe adverse effects; among them, cardiotoxic and hepatotoxic reactions stand out.¹ We recently cared for a human immunodeficiency virusinfected patient with visceral leishmaniasis who developed acute pancreatitis early in the course of treatment with sodium stibogluconate.

Report of a Case.

A 34-year-old woman with human immunodeficiency virus infection was admitted to the hospital because of high-degree fever and malaise of 1 month's duration, without any focal symptom. On physical examination she had fever (40°C), and there were small lymph nodes in the laterocervical region, hepatomegaly (3 cm), and splenomegaly (6 cm). Laboratory tests disclosed the following values: hemoglobin, 7.0 g/L; leukocyte count, 1.82x10⁹/L, with 1.32x10⁹/L neutrophils and 0.15x10⁹/L lymphocytes; platelets, 160x10⁹/L; and erythrocyte sedimentation rate, 140 mm/h. Renal function was . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?